Aspire Biopharma Rebrands to Aspire-Lakewood Holdings and Authorizes $10 Million Share Repurchase

Aspire Biopharma Holdings, Inc. has filed a Form 8-K with the Securities and Exchange Commission to change its corporate name to Aspire-Lakewood Holdings, Inc. The filing, dated September 8, 2026, states that the company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of Delaware to effect the name change. The amendment became effective on September 8, 2026.

The company notes that no stockholder approval was required for the name change because it relates solely to the corporate designation. As a result of the rebranding, the company’s common stock will continue to trade on The Nasdaq Capital Market under the ticker symbol “ASBP.” The CUSIP number for the common stock remains unchanged, and stockholders holding shares in book-entry form or through a bank, broker, or other nominee are not required to take any action.

In a press release dated September 9, 2026, the company announced that its Board of Directors has authorized a $10 million common stock repurchase program. This authorization is effective September 9, 2026. The company states that the authorization reflects its confidence in its long-term strategy and strong free cash flow generation.

The company attributes the decision to its acquisition of Dura Control Systems Corp. (DCSC). According to the press release, for the audited twelve months ended December 31, 2025, DCSC generated revenue of approximately $209.5 million and Adjusted EBITDA of $22.3 million. For the six months ended June 30, 2026, DCSC delivered revenue of approximately $103.9 million and Adjusted EBITDA of $10.5 million.

The company reports that as of September 8, 2026, it had approximately 1.5 million common shares outstanding. The Board believes the current share price does not reflect the company's financial strength or the long-term growth opportunity presented by DCSC.

Repurchases under the program may be made in open market or in privately negotiated transactions. The program does not have an expiration date, does not require the company to repurchase a specific number of shares, and may be suspended or terminated at any time without prior notice.